Department of Medicine, UAB Medical Centre, Birmingham, AL, USA.
Methods Mol Biol. 2022;2419:89-110. doi: 10.1007/978-1-0716-1924-7_6.
More than three decades ago, as a test for the amphipathic helix theory, an 18 amino acid residue peptide and its analogs were designed with no sequence homology to any of the exchangeable apolipoproteins. Based on the apolipoprotein A-I (the major protein component of high density lipoproteins, HDL) mimicking properties, they were termed as ApoA-I mimicking peptides. Several laboratories around the world started studying such de novo-designed peptides for their antiatherogenic properties. The present chapter describes the efforts in bringing these peptides as therapeutic agents for atherosclerosis and several lipid-mediated disorders.
三十多年前，作为对两亲性螺旋理论的检验，设计了一种 18 个氨基酸残基的肽及其类似物，它们与任何可交换的载脂蛋白都没有序列同源性。基于载脂蛋白 A-I（高密度脂蛋白，HDL 的主要蛋白质成分）的模拟特性，它们被称为载脂蛋白 A-I 模拟肽。世界各地的几个实验室开始研究这些全新设计的肽，以研究它们的抗动脉粥样硬化特性。本章描述了将这些肽作为动脉粥样硬化和几种脂质介导的疾病的治疗剂的努力。
